A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination With Docetaxel Versus Placebo in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Previously Treated With PD-(L)1 Inhibitors and Platinum-based Chemotherapy (CANOPY 2)
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Canakinumab (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CANOPY-2
- Sponsors Novartis; Novartis Pharmaceuticals
- 21 Nov 2019 Planned number of patients changed from 244 to 234.
- 21 Oct 2019 Planned End Date changed from 10 Aug 2021 to 25 Feb 2021.
- 21 Oct 2019 Planned primary completion date changed from 8 Mar 2021 to 25 Feb 2021.